Lung Cancer Patients With HER2 Mutations Can Now Start a Daily Targeted Pill Before Any Other Systemic Treatment

The FDA expanded sevabertinib, sold as Hyrnuo, to first-line use for HER2-mutant lung cancer. Who qualifies, trial results, and key side effects.

Have A Referral?